Member Info for Londonwolfie

Reprice not reprove

Books closed at 1945. Lower than 1060p were told they risked missing out ten minutes before the cutoff so they could reprove if needed.

And that is definite I promise

Being placed no lower than 1060p

The prices get adjusted for CGT purposes. The official adjustment factor was 0.857467 on 21/10/2019

All time high on an adjusted (i.e. current) basis was 1708.5p on 23 January 2018. Adding the 218p for M&G, this equates to 1926.5p in old money as the all-time high

Do you mean a pre clinical TYK2?

So let me get this straight. $85bn market cap company Gilead is playing silly bu99ers in order to get part of a £60m market cap company a little bit cheaper? Give yer head a wobble

HSBC Holding PLC owns 160,226,167 shares or 4.92%.

131,050,889 of these, or 4.03%, are registered to HSBC Wealth Management Client Accounts, so are most likely non-discretionary private client accounts.

The remaining 29,175,278 shares are registered to HSBC Securities Services Trading Account.

I highly doubt that any fund run by HSBC Asset management has a position - it very much looks like private client holdings.

They have already presented. There is an audio of the presentation available on Bloomberg. Can’t listen as it would wake the wife.

It does say it will be made available on the website but not on there yet from what I can see

Looks like first market maker in at 1.85 -2.05. Second lowered offer to 2.00. So from what I can see, 1.85 - 2.00 is the indicated bid/offer - up 10%.

To be fair Fadec, markets around the globe had lost a third of their value in the month preceding March 26th due to COVID. They subsequently bounced sharply on a combination of monetary and fiscal stimulus. Sareum lost half its value in that market rout before recovering sharply. Just putting some context into your comment

DG12

The January 7th RNS was not related to FLT3, it was the TYK2/JAK1 programme. It also wasn’t FDA approval; it was US patent office approval. Big big difference.

In terms of FLT3, were no £50k stage payments. There was a £50k upfront and the promise of £900K potentially had the Chinese company taken it further, which Friday’s RNS tells us they haven’t. And they weren’t trials - more about formulation (in a lab) which is where the challenges were and ultimately what was not able to be overcome.

Hope that helps ;)

To say that FLT3 had nothing to do with the share price rise since March 2020 is completely wide of the mark though. It clearly has. Admittedly it’s not the core investment case but was part of it

Brighty - I know you want to put across some positivity but you spoil your post with that (I lost over £80k in half an hour yesterday but thankfully all paper profit so have no motive to push price lower)

Hi Potnak. It would be nice if that was the case but unfortunately that description is just an oldie, for now at least

Sierra still describe themselves thus:

Sierra Oncology is a late-stage biopharmaceutical company focused on the Phase 3 execution, registration and potential commercialization of momelotinib, a novel drug that may address serious unmet needs in myelofibrosis. Momelotinib is a selective and orally bioavailable JAK1, JAK2 & ACVR1 inhibitor with a novel mechanism of action that enables it to potentially target all three hallmarks of disease in myelofibrosis: anemia, constitutional symptoms and enlarged spleen. More than 1,200 subjects have received momelotinib since clinical studies began in 2009, including more than 800 patients treated for myelofibrosis. Several of these patients have been on treatment for more than 10 years.

Think you need to change your name to snorty.

One post enquiring about a product that has the clinical code beginning with SAR. Four or five posters confirming it has nothing to do with Sareum and offering some colour behind the actual product in a friendly informative way.

Ramp of all time? Yeah right.

Stay clean snorty

Was initially discovered by TargeGen and referred to as TG101348. TargeGen was bought by Sanofi Aventis in 2010 and the drug was rebranded SAR302503. No idea why the extra R is in there - but nothing I can tell that links it to us.

Yep - its a Jak2 marketed under the name inrebic by Bristol-Myers for treatment of Myelofibrosis

Were they discussing the need to rename it LGBTyk2?

Imstaying - The shrinking of the average cost in a rising share price environment may sound like witchcraft but it is quite simple really. I will use my example: I bought 40,000 shares at an average cost of 17.2p, for a total outlay of £6,886. In the consolidation mentioned by Jurado and Way2L8, this became 4,000 shares at a book cost of 172p. I sold 1,400 shares at 494p, which raised £6917.

My account shows me banking a profit of 4,508. So, my remaining 2600 shares have a cost of £4,476 and profit of £23,500, which is correct as a CGT calculation. However, my account is a SIPP so CGT makes no difference.

The way I look at it is that I have a free ride on 2,600 shares. So, I have lowered my average cost to basically zero from 172p a share. The only way you can bring down your average in a rising share is to bank profits and hence lower average in price also must mean lower number of shares held.

same issue here Superdad. First purchase was at 1100p - that purchase now represents 1.1% of my holding but almost 14% of money invested! Have much more invested here than I ever thought and, to be honest, want. So will probably fall into the "sell too soon" camp to at least reduce my exposure - but not for a little while yet.